Target
Sialic acid immunoglobulin-like lectins (Siglec)-8
Description
Anti-Sialic acid immunoglobulin-like lectins Antibody, Non-Fucosylated (BioBet-1777ZP) is a Rat/mouse bispecific mAb monoclonal IgG antibody against Sialic acid immunoglobulin-like lectins (Siglec)-8. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Healthy; Indolent Systemic Mastocytosis; Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis,; Perennial Allergic Conjunctivitis; Chronic Urticaria Actinic Keratosis;
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Sialic acid immunoglobulin-like lectins (Siglec)-8 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Sialic acid-binding Ig-like lectin 8
Background
Sialic acid-binding Ig-like lectin 8 is a protein that in humans is encoded by the SIGLEC8 gene. This gene is located on chromosome 19q13.4, about 330 kb downstream of the SIGLEC9 gene. Within the siglec family of transmembrane proteins, Siglec-8 belongs to the CD33-related siglec subfamily, a subfamily that has undergone rapid evolution.
Alternative Names
SIGLEC8, SAF2, SIGLEC-8, SIGLEC8L, sialic acid binding Ig like lectin 8
Cellular Localization
plasma membrane
Involvement in Disease
Diseases associated with SIGLEC8 include Eosinophilic Gastritis and Congenital Disorder Of Glycosylation, Type Iic. Among its related pathways are Hematopoietic Stem Cells and Lineage-specific Markers and Innate Immune System.
Function
Putative adhesion molecule that mediates sialic acid-dependent binding to red blood cells (PubMed: 10856141, PubMed: 10625619). It is preferably combined with α-2,3-linked sialic acid. It also binds to α-2,6-linked sialic acid. The sialic acid recognition site can be masked by the cis interaction with sialic acid on the same cell surface (PubMed: 10625619). It also recognizes epitopes with terminal N-acetylneuraminic acid (sialic acid) and potential 6-O-sulfated galactose. Preferably, it binds to Gal-6 sulfated sialylated Lewis X glycan epitope (PubMed: 27357658).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1777ZP
Host
Rat/mouse bispecific mAb
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Healthy; Indolent Systemic Mastocytosis; Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis,; Perennial Allergic Conjunctivitis; Chronic Urticaria Actinic Keratosis;
